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Abstract
Background: Many antipsychotics elevate prolactin, a hormone implicated in breast cancer aetiology however no
studies have investigated antipsychotic use in patients with breast cancer. This study investigated if antipsychotic
use is associated with an increased risk of cancer-specific mortality among breast cancer patients.
Methods: A cohort of 23,695 women newly diagnosed with a primary breast cancer between 1st January 1998 and
31st December 2012 was identified from the UK Clinical Practice Research Datalink linked to English cancer-
registries and followed for until 30th September 2015. Time-dependent Cox proportional hazards models were used
to calculate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of breast cancer-specific mortality
comparing use of antipsychotics with non-use, overall, and by prolactin elevating activitiy. Analyses were repeated
restricting to patients with a history of severe mental illness to control for potential confounding by indication.
Results: In total 848 patients were prescribed an antipsychotic and of which 162 died due to their breast cancer.
Compared with non-use, antipsychotic use was associated with an increased risk of breast-cancer specific mortality
(HR 2.25, 95%CI 1.90–2.67), but this did not follow a dose response relation. Restricting the cohort to patients with
severe mental illness attenuated the association between antipsychotic use and breast cancer-specific mortality (HR
1.11, 95%CI 0.58–2.14).
Conclusions: In this population-based cohort of breast cancer patients, while the use of antipsychotics was
associated with increased breast cancer-specific mortality, there was a lack of a dose response, and importantly null
associations were observed in patients with severe mental illness, suggesting the observed association is likely a
result of confounding by indication. This study provides an exemplar of confounding by indication, highlighting the
importance of consideration of this important bias in studies of drug effects in cancer patients.
Keywords: Antipsychotics, Prolactin, Breast cancer, Survival
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: B.Hicks@qub.ac.uk
1Centre for Public Health, ICSB, Royal Victoria Hospital, Belfast BT12 6BA,
Northern Ireland
Full list of author information is available at the end of the article
Hicks et al. BMC Cancer          (2020) 20:804 
https://doi.org/10.1186/s12885-020-07320-3
Background
Antipsychotic medications are used in a range of clinical
settings including in the first-line stetting for schizo-
phrenia, other psychosis and bipolar disorder [1]. Recent
evidence form UK general practice has also shown they
are increasingly used for other indications including for
example anxiety disorders, depression, persobality disor-
ders and antention deficit hyperactivity disorder
(ADHD) [1]. Yet prescribing rates vary enormously
worldwide. The mechanism of action on psychosis is
presumed to relate to their modulation of the brain’s
dopaminergic system and in particular the blocking of
Dopamine receptor D2 receptors (D2R) in the mesolim-
bic system. However they are a very heterogenous group
of drugs with a range of actions and side effects.
A particularly common side effect of antipsychotics is
an elevation of prolactin as a consequence of their direct
effect of blocking D2R in the pituitary [2]. All antipsy-
chotics may cause a temporary increase in prolactin re-
lease but some (including first-generation antipsychotics
and some second-generation antipsychotics such as ris-
peridone and amisulpride) have been shown to prolong
elevation of prolactin levels leading to osteoporosis,
galactorrhoea and sexual dysfunction [3, 4]. The potency
of this effect on prolactin levels may be influenced not
just by the ability of the drug to bind to D2 centrally but
also by its ability to cross the blood-brain barrier (BBB)
as the pituitary lies outside the BBB.
Prolactin is implicated in both breast cancer aetiology
and progression. Studies show increased expression of
prolactin receptors on breast cancer tissue and prolactin
induced proliferation of breast cancer cells [5, 6]. Obser-
vational studies show that patients with higher plasma
prolactin levels have increased risks of breast cancer and
increased risks of breast cancer progression and mortal-
ity [7–10]. Although numerous observational studies of
antipsychotic use and breast cancer report null associa-
tions [11–16], a recent Danish study, including 4951
breast cancer cases, found increases in the risk of
oestrogen receptor positive breast cancer with long-term
antipsychotic use [17].
Given this evidence, there are concerns about the
safety of prescribing antipsychotics to breast cancer
patients with mental illnesses. For example Rahman et.al
recommended that several antipsychotics should be
avoided in breast cancer patients and in the USA, sup-
plementary package inserts contain warnings about
using antipsychotics in breast cancer patients [18]. In
contrast, researchers have argued that the published data
linking prolactin to breast cancer risk and progression
are unconvincing and insufficient to deprive breast
cancer patients of antipsychotic treatment [19]. Despite
this debate, no previous studies have investigated the
association between antipsychotic use and breast cancer
survival. Therefore, we aim to investigate whether post-
diagnostic antipsychotic use increased mortality among
a population-based cohort of breast cancer patients.
Methods
Data sources
This study was conducted using the UK Clinical Practice
Research Datalink (CPRD), linked to English cancer
registry data from the National Cancer Data Repository
(NCDR), and death registration data from the Office for
National Statistics (ONS). The CPRD contains data from
674 general practices, including more than 15 million
patients, approximately 6.9% of the UK population, and
has been shown to be representative [20]. The CPRD re-
cords information on demographics, anthropometric and
lifestyle information, clinical diagnoses and prescription
data. Previous research has found CPRD prescription
and clinical information to be of high quality and validity
[21, 22]. The CPRD are audited for data completeness
and quality. Practices meeting a predefined quality
standard are deemed ‘up to research standard’ and
included in future data extracts. The NCDR holds UK-
wide data from English cancer registries compiled from
a variety of sources including general practices, cancer
screening programmes, NHS and private hospitals, and
death certificates [23]. ONS death-registration data
provide details on the date and cause(s) of death.
CPRD obtains ethical approval to receive and supply
patient data for public health research. The study proto-
col was approved by the Scientific Advisory Committee
of the CPRD (protocol number 16_079R).
Study population
A cohort of female patients with newly-diagnosed inva-
sive breast cancer between 1998 and 2012, were identi-
fied from the NCDR. Patients with a previous record of
cancer were identified and excluded from the analysis
using a list of cancer Read codes modified for use in the
CPRD [23]. Further exclusions included those patients
diagnosed with a breast cancer before they were regis-
tered with a CPRD practice, before their practice was
deemed up to research standard, after they left a CPRD
practice, or after data was last collected from their prac-
tice by the CPRD.
Deaths were identified from ONS records. Breast
cancer-specific deaths were defined as those with breast
cancer (ICD-10 C50) recorded as the primary underlying
cause of death. Patients who died within the first year of
the study were excluded for latency considerations, as
short exposure duration is unlikely associated with can-
cer survival. Thus, patients were followed from 1 year
after breast cancer diagnosis (T0) through to the date of
death, end of registration with the general practice, last
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collection of data from the practice, end of the study
period (30th September 2015), whichever occurred first.
Exposure definition
We considered all antipsychotics available in the UK,
based on the British National Formulary (as listed in
Supplementary Table S1) [24]. Prochlorperazine, Dro-
peridol and levpromazine were not included to reduce
confounding by indication, as these are also used as
antiemetics (often used to eliviate nausa associated with
chemotherpy or terminal illness) or indicated in pallia-
tive care. The use of post-diagnostic antipsychotics was
considered as a time-varying variable in which each
person-day was classified as either antipsychotic use or
non-use, allowing patients to contribute both exposed
and unexposed person-time to the analysis. The use of a
time-varying exposure definition accounts for immortal
time bias and has been recommended previously [25].
Exposure was lagged by 1 year to account for a biologic-
ally meaningful latency time window, given that short
exposure duration is unlikely associated with cancer sur-
vival and to minimize reverse causality. Thus, patients
were considered unexposed to antipsychotics until 1 year
after their first antipsychotic prescription and considered
exposed thereafter for the remainder of follow-up (as
illustrated in Supplementary Fig. S1). To enable testing
of dose-response relationships we extracted data on the
medication prescribed, number of tablets and medica-
tion strength and calculated the defined daily dose
(DDD) for each prescription [24]. The most common
number of tablets prescribed was assumed in approxi-
mately 3% of prescriptions were this information was
missing or deemed implausible.
Potential confounders
Potential confounders included those measured at
cohort entry including, year of cancer diagnosis and age.
Co-morbid conditions have been noted to impact upon
survival in cancer patients, including breast cancer [26–
28], thus our models adjusted for various comorbities
(defined at cohort entry) including cerebrovascular dis-
ease, chronic pulmonary disease, congestive heart dis-
ease, diabetes, liver disease, myocardial infarction, peptic
ulcer disease, peripheral vascular disease, renal disease,
identified using a list of Read codes modified for use in
the CPRD) [29]. A history of severe mental illness (in-
cluding schizophrenia-like disorders, bipolar-affective
disorders and other non-organic psychoses such as delu-
sional disorder, ‘psychoses not otherwise specified’ and
severe depression with psychoses) was identified using
Read codes, as used previously [1]. Deprivation data was
available from census information, and based on the
2010 Index of Multiple Deprivation (IMD) score of the
patient’s postcode. From the NCDR we determined
treatment information within 6 months of diagnosis (in-
cluding surgery, chemotherapy, and radiotherapy). We
used CPRD prescription records to identify patients who
received hormone therapy treatment (tamoxifen or
aromatase inhibitors), and those who had used oral
contraceptives (ever use) or hormone replacement
therapy (HRT; ever use) prior to diagnosis, as these have
been shown to influence breast cancer progression [30,
31]. Finally statin and aspirin use was determined from
CPRD and modeled as time-varying covariates, defined
as users and non-users, lagged by one-year as outlined
above.
Statistical analyses
Descriptive statistics were used to summarise the
characteristics of the cohort. Time-dependent Cox
proportional hazards models were used to estimate
hazard ratios (HRs) and 95% CIs of breast cancer-
specific mortality associated with the post-diagnostic use
of antipsychotics compared with non-use. All models
were adjusted for the potential confounders measured at
cohort entry (statin and aspirin use modelled as time-
varying covariates), as outlined above. In secondary
analyses we investigated antipsychotics by type (1st
generation or 2nd generation), by prolactin elevating
and prolactin-sparing antipsychotics (as outlined in
Supplementary Table S1) and classifying antipsychotic
use as 1st generation antipsychotics only, 2nd generation
only or both. Additional analyses investigated individual
common antipsychotics including fupentixol, promazine,
trifluoperazine, haloperidol, olanzapine, risperidone and
quetiapine. Dose-response analysis was conducted to in-
vestigate high antipsychotic use compared to low use,
using cumulative DDDs. For this time-dependent
analysis patients could contribute person-time to both
non-user and user groups. Thus antipsychotic users
were included in the 1 to 182 DDDs category (low use)
until 12 months after they received their 182nd DDD
and were considered in the 182+ DDD group thereafter.
Similarly, in additional dose-response analysis, cumula-
tive DDDs were categorised into seven pre-defined
groups (1–30 DDDs, 30–90 DDDs, 90–180 DDDs, 180–
270 DDDs, 270–360 DDDs, 360–540 DDDs and > 540
DDDs).
Sensitivity analyses investigating confounding by
indication
Confounding by indication is an important source of
bias in pharmacoepidemiological studies. This bias oc-
curs when the indication for the treatment of interest is
also a risk factor for the outcome of interest, thus prog-
nostic variables in the treatment group differ from the
control group [32, 33]. A number of analyses were con-
ducted to attempt to compare antipsychotic users to
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more clinically similar antipsychotic non-users. First,
analyses were repeated restricting to patients with a
diagnosis of severe mental illness (including
schizophrenia-like disorders, bipolar-affective disorders
and other non-organic psychoses as outlined previously)
at any time prior to breast-cancer diagnosis, including
for analyses investigating first and second-generation
antipsychotics and for prolactin elevating and sparing
antipsychotics. A number of sensitivity analyses were
also repeated among the cohort of patients with severe
mental illness. Analyses were conducted investigating
mortality associated with post-diagnostic prolactin ele-
vating antipsychotics use with post-diagnostic prolactin-
sparing antipsychotics as an active cmparator. Analyses
were also conducted investigating post-diagnostic anti-
psychotic use stratified by antipsychotic use in the year
prior to diagnosis (i.e. analysis of new-users post-
diagnosis).
Sensitivity and subgroup analyses
A number of additional sensitivity and subgroup ana-
lyses were also conducted. Firstly, the primary analysis
was repeated expanding the outcome definition of breast
cancer-specific mortality to also include deaths in which
breast cancer was stated as a secondary underlying cuase
of death. Second, the primary analysis was repeated in-
vestigating the secondary outcome of all-cause mortality
(death due to any cause). Third, analyses were con-
ducted varying the length of the lag period to 6 months,
two and 4 years. Fourth, additional analysis used a sim-
plified exposure definition, with antipsychotic use de-
fined in the year post-diagnosis among patients living at
least 1 year in our analysis, controlling for immortal time
bias without requiring time-varying covariates (as illus-
trated in Supplementary Fig. S1) [34]. Fifth, as a proxy
for breast cancer oestrogen status, analyses were con-
ducted stratifying by use of tamoxifen or aromatase in-
hibitors (identified from GP prescribing records) within
6 months of breast cancer diagnosis. Further sensitivity
analyses were conducted additionally adjusting for stage,
smoking and BMI (body mass index). First analyses were
conducted using a complete case approach and second
utilising multiple imputation [35]. A multiple imputation
model for stage used ordinal logistic regression and
included age, year, cancer treatment, comorbidities,
hormone therapy use, oral contraceptive use, death indi-
cator and the baseline hazard function [35]. Similar im-
putation models were used for smoking (based upon a
multinomial logistic regression) and BMI (based upon a
multiple linear regression model). Twenty imputations
were conducted and results were combined using
Rubin’s rules [35]. A separate analysis was conducted
adjusting for stage using complete case restricted to
2997 breast cancer patients from the two cancer
registries with the highest rates of available stage (in
which stage was 85% complete). Finally, the primary
analyses were repeated with antipsychotic use defined in
the year prior to diagnosis, not excluding deaths in the
first year after diagnosis, (i.e. T0 from breast cancer
diaganosis) and adjusting for previous confounders with
the exception of cancer treatment (as cancer treatment
could be on the causal pathway). All analyses were con-
ducted using Stata/IC (version 14, TX, USA).
Results
In total, there were 23,695 patients followed for up to
16 years (beyond the one-year lag period) after breast
cancer diagnosis (with a median follow-up of 5.5 years).
During the follow-up period there were 3061 breast
cancer deaths and 848 patients were treated with an
antipsychotic medication.
Table 1 includes baseline characteristics by use of anti-
psychotics defined within the first year post breast can-
cer diagnosis for the whole cohort and among patients
diagnosed with severe mental illness. Overall, compared
to non-users, antipsychotic users were more likely to be
older, to have a higher deprivation index, to have used
aromatase inhibitors but were less likely to undergo
surgery or radiotherapy. They were also more likely to
have higher staged disease, to have other comorbidities,
to have used other medications (excluding HRT) and
were less likely to be current smokers. When restricting
the cohort to patients with a diagnosis of severe mental
illness, patterns in the differences in baseline characteris-
tics remained largely similar, however antipsychotic
users were less likely to be within the 70–79 age group
and there was no difference in surgery and radiotherapy
rates.
Table 2 presents results from primary analyses. Com-
pared with non-use, antipsychotic use was associated
with an increased risk in breast cancer-specific mortality
(HRadj, 2.25 95%CI 1.90–2.67). In analyses by cumulative
DDDs there was no evidence of a dose response relation
with high use (DDDs > 182 HRadj, 0.93 95%CI 0.56–
1.53). In analyses of cumulative DDDs categories, esti-
mates were elevated until 90–180 DDDs (HRadj 2.15
95%CI 1.32–3.49) and decreased thereafter (> 540 DDDs
HRadj 0.70 95%CI 0.31–1.59), however the number of
events among longer term users was small (Supplemen-
tary Table S2). Similar associations were observed for
first-generation antipsychotics. HRs were elevated for
promazine (HRadj, 3.34 95%CI 2.48, 4.50) and haloperi-
dol (HRadj, 4.42 95%CI 3.32–5.89). Estimates for second-
generation antipsychotics were attenuated towards the
null (all second-generation antipsychotics; HRadj 1.26
95%CI 0.91–1.73). Similar associations were observed for
those using exclusively first-generation or second-
generation antisychotics. In analyses by prolactin
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Table 1 Patient characteristics by antipsychotic use at cohort entry for all patients and by diagnosis of a severe mental illness
All breast cancer patients Breast cancer patients with severe mental illness
Antipsychotic user a Antipsychotic non-user Antipsychotic user a Antipsychotic non-user
Total 537 (2.3) 23,158 (97.7) 164 (49.1) 170 (50.9)
Year, n (%)
1998–2002 129 (24.0) 5616 (24.3) 36 (22.0) 35 (20.6)
2003–2007 203 (37.8) 8592 (37.1) 60 (36.6) 59 (34.7)
2008–2012 205 (38.2) 8950 (38.6) 68 (41.5) 76 (44.7)
Age, mean (SD) 64.7 (14) 62 (14) 62.1 (11.5) 65.4 (14.2)
0–49 93 (17.3) 4927 (21.3) 20 (12.2) 28 (16.5)
50–59 118 (22.0) 5799 (25.0) 52 (31.7) 35 (20.6)
60–69 138 (25.7) 5783 (25.0) 51 (31.1) 42 (24.7)
70–79 188 (35.0) 6649 (28.7) 41 (25.0) 65 (38.2)
Deprivation, n (%)
1 (Least Deprived) 98 (18.2) 5927 (25.6) 31 (18.9) 33 (19.4)
2 121 (22.5) 5974 (25.8) 28 (17.1) 51 (30.0)
3 116 (21.6) 4767 (20.6) 33 (20.1) 34 (20.0)
4 103 (19.2) 3848 (16.6) 32 (19.5) 32 (18.8)
5 (Most Deprived) 99 (18.4) 2633 (11.4) 40 (24.4) 20 (11.8)
Breast cancer treatment, n (%)
Surgery 350 (65.2) 18,947 (81.8) 116 (70.7) 122 (71.8)
Radiotherapy 131 (24.4) 8297 (35.8) 45 (27.4) 46 (27.1)
Chemotherapy 149 (27.7) 6658 (28.8) 37 (22.6) 48 (28.2)
Tamoxifen 211 (39.3) 9902 (42.8) 59 (36.0) 79 (46.5)
Aromatase inhibitors 152 (28.3) 4854 (21.0) 54 (32.9) 45 (26.5)
Grade, n (%)
1 67 (12.5) 3717 (16.1) 25 (15.2) 28 (16.5)
2 235 (43.8) 10,057 (43.4) 73 (44.5) 72 (42.4)
3 140 (26.1) 6907 (29.8) 41 (25.0) 52 (30.6)
4 2 (0.4) 17 (0.1) 0 0
Missing 93 (17.3) 2460 (10.6) 25 (15.2) 18 (10.6)
Stage, n (%)
1 78 (14.5) 4714 (20.4) 31 (18.9) 31 (18.2)
2 89 (16.6) 3844 (16.6) 29 (17.7) 33 (19.4)
3 13 (2.4) 733 (3.2) * *
4 17 (3.2) 291 (1.3) * *
Missing 340 (63.3) 13,576 (58.6) 95 (57.9) 93 (54.7)
Comorbidities, n (%)
Chronic pulmonary disease 98 (18.2) 3741 (16.2) 25 (15.2) 36 (21.2)
Diabetes 65 (12.1) 1440 (6.2) 16 (9.8) 16 (9.4)
Renal disease 41 (7.6) 1052 (4.5) 28 (17.1) 14 (8.2)
Cerebrovascular disease 24 (4.5) 813 (3.5) 9 (5.5) 10 (5.9)
Peptic ulcer disease 16 (3.0) 492 (2.1) 4 (2.4) 5 (2.9)
Serious mental illness 164 (30.5) 170 (0.7) 164 (100.0) 170 (100.0)
Statin use, n (%) 92 (17.1) 3454 (14.9) 38 (23.2) 29 (17.1)
Aspirin use, n (%) 97 (18.1) 2901 (12.5) 29 (17.7) 31 (18.2)
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Table 1 Patient characteristics by antipsychotic use at cohort entry for all patients and by diagnosis of a severe mental illness
(Continued)
All breast cancer patients Breast cancer patients with severe mental illness
Antipsychotic user a Antipsychotic non-user Antipsychotic user a Antipsychotic non-user
HRT use, n (%) 151 (28.1) 7571 (32.7) 56 (34.1) 62 (36.5)
Smoking status, n (%)
Current 264 (55.5) 12,705 (61.3) 71 (47.3) 80 (53.0)
Ex 92 (19.3) 4593 (22.2) 28 (18.7) 31 (20.5)
Non-smoker 120 (25.2) 3431 (16.6) 51 (34.0) 40 (26.5)
Missing 61 2429 14 19
BMI, mean (SD) 28.1 (6.1) 27.0 (5.5) 29.4 (5.9) 27.1 (6.1)
a Antisychotic use is defined as use of any antipsychotic within one year of breast cancer diagnosis
*Number suppressed due to small cell counts (< 5)
Table 2 Crude and adjusted hazard ratios for the association between the use of antipsychotics and breast cancer-specific mortality
Users Non-Users Unadjusted HR
(95% CI)
Adjusted a
HR (95% CI)N Person years Cancer deaths N Person years Cancer deaths
All antipsychotics 848 3190 165 22,847 123,106 2896 2.42 (2.07–2.83) 2.25 (1.90–2.67)
1–182 DDDs v non-user 638 2271 148 22,847 123,106 2896 2.95 (2.50–3.48) 2.56 (2.15–3.04)
182+ DDDs v non-user 210 919 17 22,847 123,106 2896 0.95 (0.59–1.53) 0.93 (0.56–1.53)
1st generation antipsychotics 558 2288 124 23,137 124,008 2937 2.62 (2.19–3.13) 2.41 (2.00–2.91)
1–182 DDDs v non-user 462 1787 115 23,137 124,008 2937 3.04 (2.52–3.67) 2.69 (2.22–3.25)
182+ DDDs v non-user 96 501 9 23,137 124,008 2937 0.94 (0.49–1.80) 0.92 (0.47–1.81)
Fupentixol 108 507 14 23,587 125,789 3047 1.36 (0.81–2.30) 1.45 (0.85–2.45)
Promazine 162 447 45 23,533 125,849 3016 4.82 (3.59–6.47) 3.34 (2.48–4.50)
Trifluoperazine 71 432 10 23,624 125,865 3051 1.11 (0.60–2.07) 1.12 (0.60–2.10)
Haloperidol 142 400 50 23,553 125,896 3011 5.71 (4.32–7.56) 4.42 (3.32–5.89)
2nd generation antipsychotics 377 1264 45 23,318 125,032 3016 1.60 (1.19–2.15) 1.26 (0.91–1.73)
1–182 DDDs v non-user 251 810 37 23,318 125,032 3016 1.96 (1.41–2.71) 1.48 (1.05–2.08)
182+ DDDs v non-user 126 454 8 23,318 125,032 3016 0.87 (0.43–1.73) 0.70 (0.34–1.44)
Olanzapine 138 546 18 23,557 125,750 3043 1.57 (0.99–2.50) 1.25 (0.76–2.03)
Risperidone 130 463 17 23,565 125,833 3044 1.67 (1.04–2.69) 1.27 (0.78–2.07)
Quetiapine 133 360 12 23,562 125,937 3049 1.55 (0.88–2.73) 1.20 (0.67–2.13)
1st generation antipsychotics only 471 1926 120 22,847 123,106 2896 2.94 (2.44, 3.53) 2.75 (2.28, 3.32)
2nd generation antipsychotics only 290 902 41 22,847 123,106 2896 1.95 (1.43, 2.65) 1.67 (1.21, 2.32)
1st and 2nd generation use 87 362 4 22,847 123,106 2896 0.64 (0.24, 1.69) 0.57 (0.21, 1.54)
Prolactin elevating antipsychotics b 668 2644 139 23,027 123,652 2922 2.50 (2.11–2.96) 2.27 (1.90–2.72)
1–182 DDDs v non-user 568 2127 130 23,027 123,652 2922 2.84 (2.38–3.39) 2.47 (2.06–2.96)
182+ DDDs v non-user 100 518 9 23,027 123,652 2922 0.91 (0.47–1.76) 0.92 (0.47–1.81)
Prolactin-sparing antipsychotics c 267 869 30 23,428 125,427 3031 1.58 (1.10–2.27) 1.27 (0.87–1.87)
1–182 DDDs v non-user 144 420 22 23,428 125,427 3031 2.24 (1.47–3.40) 1.75 (1.14–2.69)
182+ DDDs v non-user 123 448 8 23,428 125,427 3031 0.88 (0.44–1.75) 0.70 (0.34–1.44)
a Model contains age, year of diagnosis, treatment within 6months (separate variables for radiootherapy, chemotherapty, surgery, tamoxifen and aromatase
inhibitor use), comorbidities (prior to diagnosis including serious mental illness, chronic pulmonary disease, diabetes, renal disease, cerebrovascular disease,
peripheral vascular disease, myocardial infarction, peptic ulcer disease and liver disease), hormonal medication use (oral contraceptive and hormone replacement
therapy, prior to diagnosis), other medication use (statin and aspirin as time varying covariates) and deprivation (in fifths)
b Prolactin elevating antipsychotics included chlorpromazine,flupentixol,fluphenazine, haloperidol, pericyazine, perphenazine, pimozide, pipotiazine, promazine,
trifluoperazine, zuclopenthixol, amisulpride, risperidone and sulpiride
c Prolactin non-elevating antipsychotics included aripiprazole, olanzapine, quetiapine and sertindole
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elevating activity the highest HRs were observed for
prolactin-elevating antipsychotics (prolactin elevating
HRadj, 2.27 95%CI 1.90–2.72; prolactin-sparing HRadj,
1.27 95%CI 0.87–1.87) and there was no evidence of a
dose response relationships for either class.
Analyses investigating confounding by indication
Table 3 presents analyses restricting the cohort to pa-
tients with a diagnosis of severe mental illness. Overall,
compared to non-use, antipsychotic use was not associ-
ated with breast cancer-specific mortality (HRadj, 1.11
95%CI 0.58–2.14). Null associations were also observed
for 1st and 2nd generation antipsychotics (HRadj, 0.95
95%CI 0.44–2.04; HRadj, 1.10 95%CI 0.55–3.28, respect-
ively), as well as for those using exclusively first- or
second-generation antipsychotics. Likewise, no associa-
tions were observed for prolactin elevating (HRadj 0.86
95%CI 0.44–1.68) and prolactin-sparing antipsychotics
(HRadj, 1.19 95%CI 0.58–2.44), with no evidence of a
dose response relation overall, or by antipsychotic
grouping. Sensitivity and subgroup analyses conducted
among patients with a severe mental illness diagnosis
prior to breast cancer diagnosis also revealed null
associations (Table 4). In sensitivity analyses comparing
prolactin elevating antipsychotic use to prolactin-sparing
antipsychotic use, HRs were attenuated and no longer
remaining statistically significant when compared to
prolactin-sparing only (HRadj, 1.22 95%CI 0.80–1.86).
Likewise, estimates were attenuated in analyses stratify-
ing by prior antipsychotic use with null associations ob-
served among patients using antipsychotics in the year
prior to diagnosis (Table 4).
Subgroup and sensitivity analyses
Overall, sensitivity analyses remained largely similar to
the primary analyses, with similar associations observed
for all-cause mortality and with breast cancer listed at
any position on the death certificate (Table 4). HRs
remained elevated when defining antipsychotic use in
the year after diagnosis, as well as in analyses applying a
6-month lag, 2-year lag. Analysis with a 4-year lag atten-
uated estimates towards the null (HRadj1.17 95%CI 0.78,
1.73). Results remained similar for all antipsychotics and
prolactin-elevating antipsychotics when stratifying by re-
ceipt of hormonal therapy; however, estimates for
prolactin-sparing antipsychotics were more marked for
Table 3 Crude and adjusted hazard ratios for the association between the use of antipsychotics and breast cancer-specific mortality
in patients with severe mental illness
Users Non-Users Unadjusted HR
(95% CI)
Adjusteda HR
(95% CI)N Person years Cancer deaths N Person years Cancer deaths
All antipsychotics 188 898 25 146 658 23 0.97 (0.54–1.74) 1.11 (0.58–2.14)
1–182 DDDs v non-user 79 382 14 146 658 23 1.11 (0.57, 2.17) 1.37 (0.65, 2.88)
182+ DDDs v non-user 109 516 11 146 658 23 0.82 (0.39, 1.74) 0.87 (0.38, 1.98)
1st generation antipsychotics 97 511 11 237 1044 37 0.75 (0.38–1.50) 0.95 (0.44–2.04)
1–182 DDDs v non-user 47 234 6 237 1044 37 0.81 (0.34, 1.92) 0.99 (0.38, 2.58)
182+ DDDs v non-user 50 277 5 237 1044 37 0.69 (0.27, 1.81) 0.90 (0.31, 2.58)
2nd generation antipsychotics 130 565 16 204 991 32 1.08 (0.59–1.99) 1.10 (0.55–2.18)
1–182 DDDs v non-user 60 288 10 204 991 32 1.24 (0.61, 2.55) 1.44 (0.67, 3.09)
182+ DDDs v non-user 70 276 6 204 991 32 0.88 (0.36, 2.14) 0.72 (0.27, 1.93)
1st generation antipsychotics only 58 333 9 146 658 23 0.87 (0.40, 1.90) 1.07 (0.45, 2.56)
2nd generation antipsychotics only 91 387 14 146 658 23 1.16 (0.59, 2.27) 1.20 (0.55, 2.61)
1st and 2nd generation use 39 178 2 146 658 23 0.56 (0.13, 2.51) 0.80 (0.17, 3.79)
Prolactin elevating antipsychoticsb 131 681 15 203 875 33 0.73 (0.39–1.36) 0.86 (0.44–1.68)
1–182 DDDs v non-user 80 395 10 203 875 33 0.77 (0.38, 1.57) 0.87 (0.40, 1.89)
182+ DDDs v non-user 51 286 5 203 875 33 0.65 (0.25, 1.73) 0.83 (0.29, 2.40)
Prolactin non-elevating antipsychoticsc 101 417 13 233 1138 35 1.30 (0.68–2.49) 1.19 (0.58–2.44)
1–182 DDDs v non-user 32 143 7 233 1138 35 2.00 (0.88, 4.55) 2.00 (0.85, 4.69)
182+ DDDs v non-user 69 275 6 233 1138 35 0.92 (0.38, 2.22) 0.73 (0.28, 1.93)
aModel contains age, year of diagnosis, treatment within 6months (separate variables for radiootherapy, chemotherapty, surgery, tamoxifen and aromatase
inhibitor use), comorbidities (prior to diagnosis including chronic pulmonary disease, diabetes, renal disease, cerebrovascular disease, peripheral vascular disease,
myocardial infarction, peptic ulcer disease and liver disease), hormonal medication use (oral contraceptive and hormone replacement therapy, prior to diagnosis),
other medication use (statin and aspirin as time varying covariates) and deprivation (in fifths)
bProlactin elevating antipsychotics included chlorpromazine,flupentixol,fluphenazine, haloperidol, pericyazine, perphenazine, pimozide, pipotiazine, promazine,
trifluoperazine, zuclopenthixol, amisulpride, risperidone and sulpiride
cProlactin non-elevating antipsychotics included aripiprazole, olanzapine, quetiapine and sertindole
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2.02 (1.78–2.28) 1.68 (1.36–2.08)






2.13 (1.81–2.50) 1.54 (1.14–2.10)
Exposure definition






1.63 (1.30–2.04) 1.43 (0.94–2.18)






2.91 (2.51–3.37) 1.41 (1.01–1.95)






1.39 (1.06–1.81) 1.30 (0.81–2.10)
4 year lag 15,
508
67,078 1190 1.17 (0.78,
1.73)
1.12 (0.74, 1.71) 0.92 (0.39, 2.15)
Prolactin elevating versus sparing
antipsychoticsc1
3190 165 – 1.22 (0.80–1.86) 1.00
Prolactin elevating versus sparing
antipsychoticsc2
3190 165 – 1.64 (1.10–2.46) 1.00
Stratified analysis
Tamoxifen or AI used 14,
657
80,780 1707 2.19 (1.76–
2.71)
2.09 (1.65–2.65) 1.67 (1.09–2.57)
No hormonal therapy used 9038 45,516 1354 2.28 (1.73–
2.99)
2.46 (1.86–3.25) 0.67 (0.30–1.52)
Prior antipsychotic usee 389 1828 65 0.97 (0.51–
1.84)
0.77 (0.45–1.33) 1.27 (0.66–2.42)






3.08 (2.53–3.76) 1.10 (0.63–1.91)
Additional adjustment
Stage adjusted using CCf 9778 51,043 1080 2.30 (1.70–
3.10)
2.46 (1.80–3.36) 0.98 (0.47–2.06)






2.31 (1.91–2.80) 1.22 (0.82–1.81)
Stage (CC in cancer registries highest
availabilityh)
2612 13,311 338 2.40 (1.29,
4.47)
2.83 (1.53, 5.26) 0.91 (0.23, 3.52)
Smoking and BMI adjusted using CCf 18,
135
95,342 2167 2.42 (1.97–
2.96)
2.53 (2.05–3.14) 1.21 (0.73–2.01)






2.25 (1.88–2.70) 1.27 (0.86–1.87)
Patients with severe mental illness prior to diagnosis
Main analysis 334 1556 48 1.11 (0.58–
2.14)
0.86 (0.44–1.68) 1.19 (0.58–2.44)
All-cause mortality 334 1556 121 1.13 (0.75–
1.71)
1.13 (0.76–1.68) 1.12 (0.70–1.77)
6month lag 364 1730 60 1.17 (0.66–
2.08)
1.07 (0.60–1.92) 1.22 (0.64–2.30)
2 year lag 288 1245 35 1.60 (0.72,
3.58)
1.17 (0.53, 2.58) 1.74 (0.73, 4.17)
Hicks et al. BMC Cancer          (2020) 20:804 Page 8 of 12
hormonal therapy users (HRadj, 1.67 95%CI 1.09–2.47)
compared with non-users (HRadj, 0.67 95%CI 0.30–1.52).
Additional adjustment for stage and BMI and smoking
revealed largely similar estimates. Estimates were slightly
attenuated in analyses of antipsychotic use in the year
prior to diagnosis (HRadj, 1.52 95%CI 1.21–1.91)[pre-
sented in Supplementary Table S3].
Discussion
In this large population-based study, we observed in-
creases in breast cancer-specific mortality among pa-
tients using antipsychotics after diagnosis, with marked
associations observed for prolactin-elevating antipsy-
chotics. However, these associations did not appear to
follow a dose-response pattern. Importantly, analyses
restricting the cohort to patients with a history of severe
mental illness and analyses comparing prolactin elevat-
ing and prolactin-sparing antipsychotics all revealed null
associations. Thus, taken together these results appear
to suggest that the associations observed are a result of
confounding by indication i.e. that patients with severe
mental illness are at increased risk of breast cancer-
specific mortality and that these patients are more likely
to receive antipsychotics.
To the best of our knowledge, this is the first observa-
tional study to investigate the association between
antipsychotic use and breast cancer survival. It has
previously been suggested that antipsychotics, via their
effects on prolactin levels, may influence breast cancer
prognosis. Prolactin receptors have been observed in
breast cancer tissue [6] and a number of studies have
reported proliferative and metastatic effects of prolactin
in vitro [36–38]. In breast cancer patients, high prolactin
levels pre-treatment have also been associated with
increased treatment failure, recurrence and decreased
survival [7–9, 39, 40]. Indeed, in this study, while we
observed higher risks of breast cancer mortality for
prolactin-elevating antipsychotics than prolactin-sparing
in the overall cohort (HRadj, 2.27 95%CI 1.90–2.72;
HRadj,1.27 95%CI 0.87–1.87, respectively), this failed to
follow a dose-response pattern and associations were
attenuated when comparing prolactin-elevating to
prolactin-sparing antipsychotics. Nonetheless, evidence
regarding the role of prolactin on breast cancer
carcinogenesis remains conflicting [19, 41]. Additionally,
the development of prolactin receptor blocking agents
have so far proved ineffective for breast cancer treatment
[42, 43].
While we cannot rule out a causal relationship be-
tween breast cancer-specific mortality and antipsychotic
use, these findings should be interpreted with caution as
they are likely vulnerable to confounding by indication.
A number of studies have reported that patients with se-
vere mental illness, including schizophrenia and bipolar
disorder have an increased risk of breast cancer and may
have up to a 3-fold increased risk of breast cancer mor-
tality [44–46]. Women with severe mental illness may
experience delays in breast cancer detection due to a
lower awareness of breast cancer symptoms and low up-
take of mammography and as such often present with
higher stage disease [46–48]. However, in our study add-
itionally adjusting for stage revealed similar results.












Adjusted HRa Adjusted HRa Adjusted HRa
4 year lag 187 771 14 2.04 (0.50,
8.34)
1.00 (0.27, 3.66) 2.65 (0.67, 10.47)
Tamoxifen or AI used 230 1109 31 1.02 (0.41–
2.56)
0.86 (0.36–2.06) 1.27 (0.47–3.40)
Stage adjusted using MIg 334 1556 48 1.16 (0.58–
2.32)
1.02 (0.49–2.10) 1.01 (0.46–2.20)
aModel contains age, year of diagnosis, treatment within 6months (separate variables for radiootherapy, chemotherapty, surgery, tamoxifen and aromatase
inhibitor use), comorbidities (prior to diagnosis including serious mental illness (except when analysis restricted to patients with severe mental illness prior to
diagnosis), chronic pulmonary disease, diabetes, renal disease, cerebrovascular disease, peripheral vascular disease, myocardial infarction, peptic ulcer disease and
liver disease), hormonal medication use (oral contraceptive and hormone replacement therapy, prior to diagnosis), other medication use (statin and aspirin as
time varying covariates) and deprivation (in fifths)
b Anti-psychotic use based upon use in the year after breast cancer diagnosis adjusting for variables in a
c1 Prolactin elevating antipsychotics versus prolactin non-elevating antipsychotics (only prolactin elevating or both prolactin elevating and non-elevating, versus
only prolactin non-elevating)
c2 Prolactin elevating antipsychotics versus prolactin non-elevating antipsychotics (only prolactin elevating, versus both prolactin elevating and non-elevating
or only prolactin non-elevating)
d Stratified based upon hormonal therapy use (AI or tamoxifen) in the 6months after diagnosis
e Stratified based upon use of any antipsychotic medication in the year prior to diagnosis
f Complete case analysis, adjusted analysis additionally adjusted for exposure (stage or smoking and BMI)
g Using multiple imputation to impute missing exposure (stage or smoking and BMI)
h Complete case analysis additionally adjusting for stage restricted to two cancer registries in which stage was 85% complete
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Additionally, patients with breast cancer and severe
mental illness also have higher rates of smoking, other
adverse lifestyle behaviours, higher morbidity and are
less likely to receive appropriate cancer care or often ex-
perience delays in cancer treatment and poor adherence,
thus all contributing to decreased survival [47, 49–52].
Indeed, in our study antipsychotic users were less likely
to receive surgery and radiotherapy, while restricting the
cohort to patients with severe mental illness revealed
similar rates of surgery and radiotherapy among users
and non-users (although rates of chemotherapy were
higher in non-users). Moreover, in analyses in patients
with a history of severe mental illness results where at-
tenuated towards the null, including for prolactin-
elevating antipsychotics (HRadj, 0.86 95%CI 0.44, 1.68),
suggesting our overall results are likely influenced by
confounding by indication. These discrepancies in re-
sults observed for the overall cohort and when restrict-
ing to patients with severe mental illness, and comparing
prolactin elevating antipsycotics to prolacting–sparing
antipsychotics provide a clear example of the importance
of accounting for confounding by indication in pharma-
coepidemiolgical studies in cancer patients. However,
while the potential association between prolactin-
elevating antipsychotics and breast cancer survival
requires further exploration these results when restrict-
ing to patients with similar diagnoses should provide
some reassurance for clinicians around the use of
antipsychotics in breast cancer patients, in whom
psychiatric disorders are often undertreated [19].
Strengths and limitations
This study had a number of strengths. Firstly, this was a
large population-based study, utilizing high quality data
including registry confirmed breast cancer and had a
long follow-up period of up to 16 years (beyond the
1 year post-cohort lag period). Linkage to the ONS
death registration data allowed for robust verification of
death, and facilitated breast cancer-specific analysis
which should be more sensitive to small changes in
disease-specific mortality and less susceptible to con-
founding by indication than all-cause mortality [53, 54].
Furthermore, we used a time varying exposure definition
that eliminated immortal time bias while also account
for latency considerations. Finally, the use of the CPRD
and NCDR allowed us to adjust for several potentially
important confounders including for example age, co-
morbidities and smoking status.
However, this study also had a number of limitations.
First, although we were able to adjust for a number of
important confounders we also lacked information on
other potential confounders such as ethnicity or dietary
factors. Furthermore, tumour stage was missing for a
proportion of our cohort and thus omitted from our
main analyses. Reassuringly, our results remained con-
sistent when adjusting for stage using a range of ap-
proaches, for instance, using multiple imputation for
missing stage and in complete case analyses of stage re-
stricted to cancer registries with stage availability of over
85%. We also lacked information on hormone receptor
status however we were able to adjust for tamoxifen and
aromatase inhibitor use as a proxy for oestrogen status.
While we had detailed information on antipsychotic
drug use from GP prescribing data, including type,
strength and quantity, this reflects those written by gen-
eral practitioners, rather than dispensing information,
thus misclassification of exposure is possible if patients
did not adhere to the treatment regimen or received pre-
scriptions from specialists. However we were able to
conduct analyses by cumulative DDDs (e.g. > 182 DDDs)
for whom non-compliance is less of a concern. Add-
itionally, although previous studies have reported overall
high levels of diagnostic validity in CPRD, to the best of
our knowledge no previous study has investigated the
validity of psychosis or bipolar disorder diagnoses in
CPRD [55, 56]. Reassuringly, a previous study in UK
general practice did report high accuracy and complete-
ness of psychosis diagnoses however misclassification of
these cannot be ruled out [57]. Finally, while antipsy-
chotics are not available over the counter in the UK,
which negates exposure misclassification due to over-
the-counter use, antipsychotic prescriptions from
secondary care are not captured within the CPRD so
some exposure misclassification is possible.
Conclusion
This was the first study to date to examine the associ-
ation between post-diagnostic antipsychotic use and
survival in patients with breast cancer. While we
observed increases in breast cancer-specific mortality,
the lack of a dose response relation, and the null associa-
tions observed in patients with severe mental illness,
suggest the observed association is likely a result of
confounding by indication. This highlights the import-
ance of controlling for this bias in studies of drug effects
in cancer patients and should provide some reassurance
to clinicans on the use of antipsychotic medicatons in
women diagnosed with breast cancer.
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